Abraxis BioScience: Difference between revisions

Abraxis BioScience
Industry	Pharmaceutical
Founded	2001 in Los Angeles, California
Founder	Dr. Patrick Soon-Shiong
Defunct	2010
Headquarters	Los Angeles, United States
Key people	Mr. Rick Click, Chief Information Officer and Global IT Officer; Dr. Nguyen V. Dat Ph.D., Vice President of Clinical Research
Products	Protein-based therapeutics and technologies for treatment of cancer and other critical illnesses
Brands	Abraxane
Services	Cancer drugs
Revenue	US$359 million (2009)
Operating income	US$−113 million (2009)
Net income	US$−104 million (2009)
Total assets	US$1.068 billion (2009)
Total equity	US$846 million (2009)
Owner	Celgene
Number of employees	885 (2009)

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 12:54, 1 September 2020

Abraxis BioScience was a global biopharmaceutical, and nano-medicine company that developed treatments for critically ill patients. It had over 2000 employees worldwide inb 2007.^[3] Abraxis's portfolio included the world's first protein-based nanoparticle chemotherapeutic compound, called nab Technology.^[4] From this the company developed Abraxane, a treatment for metastatic breast cancer.^[5]

In 2010, Abraxis BioScience was acquired by Celgene Corporation.^[6]

History

Abraxis was incorporated in 2001 in Los Angeles.^[1] Besides cancer treatments, it provided treatment for multiple sclerosis, Alzheimer's, and some cardiovascular diseases.^[1] It had manufacturing plants in Melrose Park, Illinois and Phoenix, Arizona.^[1]

In August 2007, Abraxis announced it would undergo a restructuring to separate its "hospital-based products business" from its "proprietary products business" into two public companies; this would involve the merging of Abraxis Oncology and Abraxis Research subunits to form a new Abraxis Bioscience (Abraxis Bioscience, Inc., Nasdaq: ABII), and the spinoff of Abraxis Pharmaceutical Products (APP, Inc., Nasdaq: APPX).^[7] This reorganization was completed in November 2007.^[8] During the reorganization, the new Abraxis Bioscience was known briefly as New Abraxis.^[8]

In 2010, Abraxis BioScience was acquired by Celgene Corporation.^[6] Per Celgene's website, as of at least 2016 Abraxis no longer exists as a named division within Celgene.

References

^ ^a ^b ^c ^d "Company Overview of Abraxis BioScience, Inc". Bloomberg. Retrieved October 17, 2016.
^ ^a ^b ^c ^d ^e ^f "Abraxis BioScience 2009". Abraxis BioScience. Abraxis BioScience.{{cite web}}: CS1 maint: url-status (link)
^ BioPortfolio, 2007, "InDepth Summary", 10/11/2009^{[dead link]}
^ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
^ Hoovers. Archived 2015-09-24 at the Wayback Machine
^ ^a ^b Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
^ Van Arnum, Patricia (1 August 2007). "Abraxis BioScience Plans to Separate into Two Companies". Pharmaceutical Technology. Archived from the original on 24 September 2015. Retrieved 2015-08-07 – via Highbeam Research.
^ ^a ^b Gopalakrishnan, Lisa (13 November 2007). FORM 8-K (Report). United States Securities and Exchange Commission. Retrieved 2015-08-07.

External links

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

[bberg-1] "Company Overview of Abraxis BioScience, Inc". Bloomberg. Retrieved October 17, 2016.

[abr-2] ^ ^a ^b ^c ^d ^e ^f "Abraxis BioScience 2009". Abraxis BioScience. Abraxis BioScience.{{cite web}}: CS1 maint: url-status (link)

[3] BioPortfolio, 2007, "InDepth Summary", 10/11/2009^{[dead link]}

[4] Abraxis BioScience, 2008, "Nab Technology", 10/11/2009

[5] Hoovers. Archived 2015-09-24 at the Wayback Machine

[ir.celgene.com-6] Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.

[7] Van Arnum, Patricia (1 August 2007). "Abraxis BioScience Plans to Separate into Two Companies". Pharmaceutical Technology. Archived from the original on 24 September 2015. Retrieved 2015-08-07 – via Highbeam Research.

[:0-8] Gopalakrishnan, Lisa (13 November 2007). FORM 8-K (Report). United States Securities and Exchange Commission. Retrieved 2015-08-07.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

@@ Line 26: / Line 26: @@
 | brands              = [[Abraxane]]
 | services            = Cancer drugs
+| revenue = {{increase}} {{US$|359 million}} {{small|(2009)}}<ref name="abr">{{Cite web|url = https://files.docoh.com/10-K/0001193125-10-055402/d10k.htm.gz#toc|title = Abraxis BioScience 2009 |date= |website=Abraxis BioScience |publisher = Abraxis BioScience |access-date= |url-status=live}}</ref>
+| operating_income = {{negative decrease}} {{US$|-113 million}} {{small|(2009)<ref name="abr" />}}
+| net_income = {{negative decrease}} {{US$|-104 million}} {{small|(2009)<ref name="abr" />}}
+| assets = {{decrease}} {{US$|1.068 billion}} {{small|(2009)<ref name="abr" />}}
+| equity = {{decrease}} {{US$|846 million}} {{small|(2009)<ref name="abr" />}}
+| num_employees = 885 {{small|(2009)<ref name="abr" />}}
 | owner               = [[Celgene]]
 | rating              = <!-- for BANKS ONLY -->